REVIEW Open Access

Current status and strategies of long noncoding RNA research for diabetic cardiomyopathy

Tarun Pant¹,⁶, Anuradha Dhanasekaran⁶, Juan Fang³, Xiaowen Bai⁴,⁵, Zeljko J. Bosnjak¹,⁵, Mingyu Liang⁵ and Zhi-Dong Ge²*

Abstract

Long noncoding RNAs (lncRNAs) are endogenous RNA transcripts longer than 200 nucleotides which regulate epigenetically the expression of genes but do not have protein-coding potential. They are emerging as potential key regulators of diabetes mellitus and a variety of cardiovascular diseases. Diabetic cardiomyopathy (DCM) refers to diabetes mellitus-elicited structural and functional abnormalities of the myocardium, beyond that caused by ischemia or hypertension. The purpose of this review was to summarize current status of lncRNA research for DCM and discuss the challenges and possible strategies of lncRNA research for DCM. A systemic search was performed using PubMed and Google Scholar databases. Major conference proceedings of diabetes mellitus and cardiovascular disease occurring between January, 2014 to August, 2018 were also searched to identify unpublished studies that may be potentially eligible. The pathogenesis of DCM involves elevated oxidative stress, myocardial inflammation, apoptosis, and autophagy due to metabolic disturbances. Thousands of lncRNAs are aberrantly regulated in DCM. Manipulating the expression of specific lncRNAs, such as H19, metastasis-associated lung adenocarcinoma transcript 1, and myocardial infarction-associated transcript, with genetic approaches regulates potently oxidative stress, myocardial inflammation, apoptosis, and autophagy and ameliorates DCM in experimental animals. The detail data regarding the regulation and function of individual lncRNAs in DCM are limited. However, lncRNAs have been considered as potential diagnostic and therapeutic targets for DCM. Overexpression of protective lncRNAs and knockdown of detrimental lncRNAs in the heart are crucial for defining the role and function of lncRNAs of interest in DCM, however, they are technically challenging due to the length, short life, and location of lncRNAs. Gene delivery vectors can provide exogenous sources of cardioprotective lncRNAs to ameliorate DCM, and CRISPR–Cas9 genome editing technology may be used to knockdown specific lncRNAs in DCM. In summary, current data indicate that lncRNAs are a vital regulator of DCM and act as the promising diagnostic and therapeutic targets for DCM.

Keywords: Long noncoding RNAs, Diabetic cardiomyopathy, H19, MALAT1, MIAT, SENCR, MT-LIPCAR

Background

Diabetic cardiomyopathy (DCM) refers to diabetes-associated changes in the structure and function of the myocardium that are not directly attributable to other confounding factors such as coronary heart disease or hypertension [1]. It is estimated that DCM occurs in approximately 12% of diabetic patients [2]. DCM is associated with the development of overt heart failure and worse prognosis of diabetic patients [3, 4]. A strategy for prevention and treatment in order to improve the prognosis of DCM has not been established [5–7].

Long noncoding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides which, although not having the function of direct coding proteins, can regulate the expression of genes at transcriptional, post-transcriptional, and translational levels [8]. Over the past decade, lncRNAs have received widespread attention as potentially new and crucial players of biological regulation [9, 10]. Their cell-type and tissue-specific expression in health and cardiovascular disease provides the avenue for the
Emerging studies find that lncRNAs are aberrantly regulated in DCM, and impacting the expression of specific lncRNAs is capable of regulating the pathophysiological process of DCM [13–15]. Although the detailed data regarding the role of specific lncRNAs in DCM are limited, they are increasingly identified as a vital regulator of DCM in experimental animals. To get insight into current status of lncRNA research for DCM, we used PubMed and Google Scholar databases to search systematically the published articles that are involved in lncRNAs and DCM. Major conference proceedings of diabetes mellitus and cardiovascular disease occurring between January, 2014 to August, 2018 were also searched to identify unpublished studies that may be potentially eligible. Based on the data obtained from these databases, we present an overview of lncRNA research for DCM. We also discuss the challenges and possible strategies of lncRNAs as diagnostic and therapeutic targets for DCM.

Diabetes-induced cardiac damage
Diabetes mellitus affects the heart through various mechanisms including metabolic disturbance (suppressed glucose oxidation, enhanced fatty acid metabolism, hyperinsulinemia, insulin resistance, accumulation of advanced glycation end-products, etc.), subcellular component abnormalities, microvascular impairment, and autonomic dysfunction [16, 17]. Eventually myocardium develops local inflammation, coronary arterial endothelial dysfunction, necrosis, apoptosis, autophagy, fibrosis, atherosclerosis, steatosis, and ventricular hypertrophy (Fig. 1) [18, 19]. These pathological changes in the structure, morphology, and function of the heart develop in diabetic patients, especially patients with type 2 diabetes mellitus (T2DM), even without the presence of ischemic heart disease and hypertension, termed diabetic cardiomyopathy (DCM) [1]. It is estimated that DCM occurs in approximately 12% of diabetic patients [2]. Clinical studies indicate that DCM increases the risk of overt heart failure and worsens the prognosis in diabetic patients [3, 4].

Animal models of DCM are critically important for us to advance the understanding of pathogenic mechanisms of DCM and discover new diagnostic and therapeutic targets for DCM. Over the past thirty years, investigators have developed many rodent models of diabetes mellitus and DCM [19, 20]. They are able to provide many advantages in the availability of adequate healthy controls and the absence of confounding factors such as marked differences in age, concomitant pathologies, and pharmacological treatments. Among these models, streptozotocin (STZ)-induced cardiomyopathy of type 1 diabetes mellitus (T1DM) and leptin receptor deficient (db/db)- or leptin deficient (ob/ob)-cardiomyopathy of T2DM are frequently used in the study of lncRNAs [5, 20, 21].

LncRNAs in the heart
LncRNAs represent one of the most prominent but least understood transcriptome in the heart. According to the NONCODE database (http://www.noncode.org/, version 5), there are 172,216 and 131,697 lncRNA transcripts for humans and mice, respectively. Thousands of lncRNAs have been identified to express abundantly in the myocardial tissues [22–24]. Many of these lncRNAs are dynamically transcribed during the development, differentiation, and maturation of cardiac myocytes [25–27].

LncRNAs have been known to control and regulate the expression of broad ranges of genes in cardiomyocytes [28, 29]. Similar to protein-coding RNAs, individual lncRNAs have specific subcellular distribution that is critical for their functions [30, 31]. Some lncRNAs are enriched in the nucleus and are involved in regulating nuclear processes, such as DNA replication-associated biological processes, mRNA transcription, and RNA processing [23, 32]. In the nucleus, lncRNAs can interact with DNA to form RNA-DNA complexes to reprogram gene expression, act as molecular scaffold, activate or suppress transcription [33, 34]. Other lncRNAs are enriched in the cytoplasm where they can impact
protein localization or modulate mRNA stability and translation [35]. LncRNAs can also bind mRNA transcripts to either stabilize or promote translation, cause steric hindrance to block translation (e.g., acting as decoys), regulate RNA splicing and stability, and act as a sponge for microRNAs [36–38]. In the cytoplasm, lncRNAs can interact with proteins to mediate protein trafficking and signaling and impact the function of bound proteins [39].

LncRNA-mediated regulation of gene expression in the heart has been known to involve a variety of mechanisms [40, 41]. Some lncRNAs (for example, cardiac-specific lncRNA Myheart) can interact with chromatin remodeling factors to reprogram gene expression [28]. Some lncRNAs (e.g., the lncRNA Braveheart) can guide chromatin-modifying complexes to their required genomic destination and serve as docking stations for complex recruitment (acting as scaffolding) [42]. Certain lncRNAs (e.g., the cardiac-enriched lncRNA Upperhad) activate transcription of certain genes by guiding transcription factors to their promoters [43, 44]. Particular lncRNAs (e.g., the lncRNA cardiac autophagy inhibitory factor) are capable of suppressing transcription by sequestering transcription factors [45]. Some lncRNAs (e.g., the lncRNA myocardial infarction-associated transcript [MIAT]) can bind to complementary microRNAs (e.g., microRNA-24) via base pairing to sequester them (acting as “microRNA sponges”) [46]. Various lncRNAs (e.g., the lncRNA metastasis-associated lung adenocarcinoma transcript 1 [MALAT1]) can interact with mRNA to regulate their translation and splicing [47, 48]. Other lncRNAs (e.g., cardiac autophagy inhibitory factor) can interact with proteins to mediate their trafficking and signaling and regulate the function of bound proteins [45].

LncRNAs play crucial roles in various cardiac diseases [38, 45, 49, 50]. LncRNAs can be targeted to change the physiological function of cardiac myocytes [51, 52]. In cardiac disease, lncRNAs are regulated in a cell type/tissue-specific manner [53, 54]. Manipulating the expression of specific lncRNAs with genetic and pharmacological approaches impacts the severity of myocardial ischemia/reperfusion injury, cardiac hypertrophy, heart failure, and diabetic vascular complications. Thus, certain lncRNAs that are conserved in the heart may have therapeutic potential on various heart diseases [12, 14, 55]. Moreover, some circulating lncRNAs have been proposed to be the biomarker of cardiac disease [56].

**Regulation and function of specific lncRNAs in DCM**

Specific lncRNAs have been identified to express differentially in the heart with DCM [15, 37, 57, 58]. The aberrant expression of specific lncRNAs is associated with the pathophysiological process of DCM, such as oxidative stress, inflammation, apoptosis, myocardial fibrosis, and autophagy (Fig. 2) [15, 37, 57, 58]. Manipulating specific lncRNAs to alter their expression is able to ameliorate DCM [37, 57, 58]. Despite the limited data regarding the regulation and function of specific lncRNAs in DCM, lncRNAs are considered as a promising target/candidate for the treatment and diagnosis of DCM. In this section, we discuss several of the lncRNAs that may have a good potential as a target/candidate for the treatment and diagnosis of DCM (Table 1).

**H19**

H19 is a 2.3-kb lncRNA which is transcribed from H19/insulin-like growth factor-II (IGF2) genomic imprinted cluster located on human chromosome 11p15.5 (syntenic to mouse chromosome 7) [59]. H19 and IGF2 genes are expressed in a monoallelic fashion from the maternal and paternal chromosomes, respectively [60, 61]. H19 is transcribed by a polymerase II [62]. H19 transcripts start from the blastocyst stage and reach a high level in the tissues of endodermal, mesodermal, and ectodermal origins [63]. After the birth, H19 expression will be inhibited in most of mammalian tissues [64]. However, H19 remains in high accumulation in mature myocardium of both mice and humans possibly due to enhanced RNA stabilization during cardiomyocyte differentiation [65]. Both primary sequence and secondary structures of H19 show a great extent of conservation among mammals [66].

H19 has recently been identified as an important regulator of the cardiomyopathy of T1DM in experimental rats [57, 58]. Sprague-Dawley rats injected with STZ developed the cardiomyopathy of T1DM with decreased expression of cardiac H19 [57, 58]. Overexpression of H19 in myocardial tissues caused decreases in oxidative stress, inflammation, apoptosis, and autophagy, leading to the amelioration of DCM [57, 58].

H19 serves as template for microRNA-675 expression from H19 first exon [67, 68]. Since microRNA-675 has multiple targets in diverse signaling pathways, H19 is able to regulate a number of biological processes via microRNA-675. For example, the H19/microRNA-675 reduces high glucose-induced apoptosis by targeting voltage-dependent anion channel 1 which is a critical protein required for the mitochondria-mediated apoptosis [58, 69]. In addition, by down-regulating GTP-binding protein Di-Ras-3, the H19/microRNA-675 promotes the phosphorylation of the mechanistic target of rapamycin and inhibits activated autophagy in cardiomyocytes exposed to high glucose [57]. Another pattern of H19 exerting its function is through interacting with proteins and microRNAs. H19 is capable of being folded into a special secondary structure, which allows it to serve as a platform and collect relative proteins [70]. Multiple proteins have been identified to associate with H19, including the RNA binding proteins, KH-type splicing regulatory proteins, inner membrane protease 1,
the Hu family of RNA-binding proteins, heterogeneous nuclear ribonucleoprotein U, polypyrimidine tract-binding protein 1, the DNA/chromatin modification factors, S-adenyl-L-homocysteine hydrolase, polycomb repressive complex 2, p53, and isoleucyl tRNA synthetase of mitochondria [68]. These proteins are actively involved in a wide variety of physiological and pathological processes, such as RNA metabolism, gene transcription, and epigenetic modification [68]. MicroRNAs are another group of partners that are essential for H19 to exert its function. It is evident that H19 interacts with Let-7, microRNA-138, microRNA-200a, microRNA-106a, and microRNA-141 [68].

IGF2 proteins are an important growth factor during pregnancy, where they promote both fetal and placental growth [71, 72]. However, the overexpression of IGF2 and its receptors in acute hyperglycemia and diabetes is associated with the progression of DCM by triggering cardiac hypertrophy and apoptosis [73]. The effect of H19 overexpression on the levels of myocardial IGF2 in adults remains unclear. In embryos, the overexpression of H19 results in a decrease in IGF2 expression due to a cis effect of the H19 locus on the adjacent IGF2 gene [74]. It is reasonably believed that IGF2 levels are decreased too in H19-overexpressing animals, and decreased IGF2 contributes to the beneficial effects of H19 overexpression on DCM.

In summary, cardiac H19 is downregulated in DCM, and transgenic overexpression of H19 improves DCM by attenuation of myocardial oxidative stress, inflammation, apoptosis, and autophagy.

**MALAT1**

MALAT1 is a nuclear transcript localized to the nuclear speckles, a nuclear domain for storage and/or the sites of pre-mRNA splicing [75]. Pre-mRNAs splicing is a pivotal step between transcription and translation of most eukaryotic mRNAs [76]. MALAT1 interacts with several serine/arginine proteins, such as serine/arginine-rich splicing factors and spliceosomal proteins, to regulate pre-mRNA splicing [77–79]. In addition, MALAT1 is involved in nuclear organization and epigenetic modulation of gene expression [80, 81]. MALAT1 was abundantly expressed in cardiac myocytes and highly conserved across mammalian species [82, 83]. In the rat cardiomyopathy of T1DM induced by streptozotocin, MALAT1 in myocardial tissues was upregulated [15, 84]. The knockdown of MALAT1 with the small interfering RNA to

---

**Table 1** Regulation and function of specific long noncoding RNA in DCM

| LncRNAs   | Models               | Species | Regulation during DCM | Function in DCM                                                                                           | References |
|-----------|----------------------|---------|-----------------------|------------------------------------------------------------------------------------------------------------|------------|
| H19       | STZ-included T1DM    | Rats    | Down                  | Suppress oxidative stress, inflammation, apoptosis, and autophagy                                        | [57, 58]   |
| MALAT1    | STZ-included T1DM    | Rats    | Up                    | Suppress inflammation and apoptosis                                                                          | [15, 84]   |
| MIAT      | STZ-included T1DM    | Rats    | Up                    | Decrease apoptosis                                                                                            | [37]       |
| SENCR     | db/db T2DM           | Mice    | Down                  | Promote proliferation and migration of smooth muscle cells                                                 | [87]       |
| MT-LIPCAR | T2DM                 | Humans  | Down                  | Not available                                                                                                | [13]       |
attenuate the expression of MALAT1 in diabetic hearts significantly attenuated inflammation and apoptosis and improved DCM [15, 84]. Thus, the upregulation of MALAT1 represents a critical pathogenic mechanism for DCM.

In short, cardiac MALAT1 is upregulated in DCM, and the knockdown of MALAT1 improves DCM by attenuation of myocardial inflammation and apoptosis.

**MIAT**

MIAT is first identified to be associated with myocardial infarction in a genome-wide association study in 2006 [85]. Before that, MIAT was also known as RNCR2, 2 AK02836 or GOMAFU. MIAT may function as a competing endogenous RNA to upregulate the expression of death-associated protein kinase-2 by sponging miR-22-3p, which consequently leads to the apoptosis of cardiac myocytes [37]. Like MALAT1, the expression of cardiac MIAT was significantly upregulated in Sprague-Dawley rats with the cardiomyopathy of T1DM [37]. The knockdown of MIAT with MIAT-shRNA resulted in improvement of DCM and reduction of apoptosis of cardiac myocytes [37]. The inhibitory effect of MIAT knockdown on apoptosis is attributed to a decrease in the expression of death-associated protein kinase-2. Taken together, the upregulation of cardiac MIAT contributes to the pathogenesis of DCM.

**Smooth muscle and endothelial cell-enriched migration/differentiation-associated long noncoding RNA (SENCR)**

SENCR is a vascular cell-enriched lncRNA [86]. It promotes the proliferation and migration of smooth muscle cells through regulation of forkhead box protein O1 and transient receptor potential cation channel 6. However, SENCr was down-regulated in T2DM db/db mice and in vascular smooth muscle cells exposed to high glucose [87]. The overexpression of SENCr reversed the inhibitory effect of high glucose on the proliferation and migration of mouse vascular smooth muscle cells. Both clinical and experimental studies indicate that impaired vascular smooth muscle cells by diabetes and high glucose contribute to the increased incidence of DCM [88]. Although there are no reports about the direct impacts of SENCr on DCM, the downregulation of cardiac SENCr may contribute to the pathogenesis of DCM.

**The mitochondrially encoded long non-coding cardiac associated RNA (MT-LIPCAR)**

MT-LIPCAR (uc022bgs.1, Gene ID: 103504742) is a 781-nucleotide lncRNA which is possibly transcribed from mitochondrial DNA [89]. It can cross the membrane barrier and is released into the circulation. Although there are a large number of RNase in plasma [90], MT-LIPCAR is stable in blood serum/plasma [13, 49, 91]. Recently, de Gonzalo-Calvo et al. analyzed lncRNAs derived from the serum of 48 patients with cardiomyopathy of T2DM and 12 healthy volunteers [13]. MT-LIPCAR levels in plasma were positively associated with left ventricular diastolic dysfunction. Moreover, MT-LIPCAR was strongly correlated with waist circumference, plasma fasting insulin, subcutaneous fat volume, and high-density lipoproteins-C. Collectively, MT-LIPCAR may be an independent predictor of diastolic dysfunction in T2DM patients with DCM [13].

In the clinic, the specific diagnosis of DCM is difficult, since the patients are asymptomatic in the early and middle stages and may concomitantly suffer from ischemic heart disease or hypertension during the late stage [7, 92, 93]. The significant increase in the levels of specific lncRNAs in serum/plasma of patients with DCM, such as MT-LIPCAR, could make lncRNAs specific biomarkers for the diagnosis and prognosis of DCM. A clinical trial recently suggests that MT-LIPCAR in plasma may serve as a promising biomarker of DCM [13]. The value of MT-LIPCAR and other circulating lncRNAs as diagnostic and prognostic markers in DCM needs to be validated. Large multicenter randomized, controlled trials with MT-LIPCAR need to be conducted in patients with DCM.

**Antisense non-coding RNA in the INK4 locus (ANRIL)**

ANRIL [alias cyclin dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) and P15 antisense RNA (P15AS)] is a 3.8 kb lncRNA transcribed from the short arm of human chromosome 9 on p21.3 [94]. ANRIL and the adjacent protein coding genes, cyclin dependent kinase inhibitor 2A (CDKN2A) and cyclin dependent kinase inhibitor 2B (CDKN2B), locate on chromosome 9p21 [95]. The CDKN2A gene encodes several transcripts/proteins, the p16 protein of which functions as inhibitors of cyclin-dependent kinase 4 [96, 97]. The CDKN2B gene encodes cyclin-dependent kinase 4 inhibitor B that functions as a cell growth regulator that control cell cycle G1 progression [98]. ANRIL is an antisense of the CDKN2B gene and is transcribed by RNA polymerase II and spliced into multiple linear and circular isoforms in a tissue-specific manner [99]. ANRIL is capable of recruiting polycomb group proteins to modify the epigenetic chromatin state and binding to a site or sequence to regulate gene expression [100]. It is well known to know that single nucleotide polymorphisms in the human chromosome 9p21 locus are associated with diabetes, cardiovascular disease, and multiple cancers [101–106]. Recent studies have identified ANRIL as a highly susceptible region for T2DM, coronary artery disease, and hypertension [107]. Although there is no report regarding the role of ANRIL in DCM, it is
reasonably believed that ANRIL might be involved in the pathogenesis of DCM.

In summary, ANRIL is a potential candidate that is associated with the pathogenesis of DCM.

**Challenges and potential strategies of lncRNA research for DCM**

LncRNAs may be a promising target and/or candidate as biomarkers of DCM diagnosis and for the treatment of DCM. However, at present the function and regulation of thousands of IncRNAs in DCM are still ambiguous. Recently, we performed a systemic microarray-based analysis of the cardiac expression profiles of IncRNAs in T2DM db/db mice on a genetic background of C57BL/6 mice with and without DCM. Among the 23,578 IncRNAs identified, 1479 were differentially expressed in the myocardium of db/db mice between with DCM and without DCM [108]. These results suggest that at least 1479 IncRNAs might be involved in DCM in obese type 2 db/db mice. Determining the individual functionality of these IncRNAs is important for good understanding of cardiac developmental biology and DCM. For the study of individual IncRNAs in DCM, the following questions should be considered: Do IncRNAs contribute to the pathogenesis of DCM? How stable are the IncRNAs in circulation? Is their stability altered in diabetes mellitus and cardiac dysfunction? Are IncRNAs toxic? What are the pharmacokinetics of the IncRNAs? Answering these questions will be important as we study the individual IncRNAs and their role in diagnosis and treatment of DCM.

Some IncRNAs are protective to DCM, such as H19. These IncRNAs are down-regulated in DCM [57], and their overexpression in the heart is considered as a therapeutic strategy for DCM [58]. Owing to the length of IncRNA molecules their overexpression in cardiomyocytes is a complicated matter. Moreover, the long modified transcript is difficult to cross the membrane barrier. Thus, its efficient in vivo delivery would be difficult. Recent studies have reported that gene delivery vectors are capable of provide exogenous expression of the desired IncRNAs [38]. Utilization of gene delivery vectors, like engineered adeno-associated virus, is an alternative approaches to increase the expression of protective IncRNAs in the heart to ameliorate DCM.

Up-regulation of detrimental IncRNAs in DCM, such as MALAT1 and MIAT, could make them promising therapeutics targets for DCM [109]. However, in vivo inhibition of detrimental IncRNAs is a challenge mainly due to their short half life as they are easily degraded by nuclease in bio fluids and the length of IncRNA transcripts. At present, the approaches which are used to manipulate IncRNAs in vivo include mainly the use of small interfering RNAs, antisense oligonucleotides, and the 5′ and 3′ end-modified antisense oligonucleotides, GapmeRs [53, 110]. Each of these approaches have their own advantages and disadvantages. Small interfering RNAs specifically bind to complementary sequences and inhibit the expression of IncRNA targets [111, 112]. Antisense oligonucleotides are capable of targeting specific genes or transcripts directly through Watson-Crick base pairing, and they thus can reduce the levels of IncRNAs of interest [113]. Locked nucleic acid GapmeRs can modulate target IncRNA expression, block IncRNA activity, or induce enzyme-mediated degradation [53, 114]. Despite the potential therapeutic value of small interfering RNAs, antisense oligonucleotides, and GapmeRs in treating human disease, the effects of these approaches may have varied efficacy within the cell due to poor accessibility. Many studies have made use of antisense oligonucleotides to knockdown IncRNAs successfully for functional studies in mice or rats [115–117]. Compared with small interfering RNAs, antisense oligonucleotides are able be a better approach since cytoplasmic IncRNAs are efficiently ablated using small interfering RNA. To inhibit upregulated IncRNAs that show co-localization, the hybrid approach works the best [111].

Some IncRNAs are refractory to inhibition by either antisense oligonucleotides or small interfering RNAs. This may be related to the subcellular localization of the IncRNAs, which is not accessible to either RNase H or the interfering RNA machinery [111]. Another cause may be that the IncRNAs are highly structured or blocked due to excessive protein binding or hybridizing to other cellular nucleic acids. To overcome these hurdles, it is necessary to produce a high-throughput method to delete IncRNAs. Emerging studies suggest that CRISPR–Cas9 genome editing technology is able to quickly and effectively delete IncRNAs [118, 119]. Despite no reports about the utilization of CRISPR–Cas9 genome editing technology in DCM, this technology is a potential tool to delete the IncRNAs of interest and modulate the expression of IncRNAs in DCM.

In short, both overexpression of protective IncRNAs and knockdown of detrimental IncRNAs in the heart are crucial for defining the role and function of the IncRNAs of interest in DCM. Either approach is technically challenging due to the length, short life, and location of the IncRNAs of interest. In addition to traditional utilization of small interfering RNAs, antisense oligonucleotides, and GapmeRs to inhibit the IncRNAs of interest, CRISPR–Cas9 genome editing technology is a potential tool to knockdown specific IncRNAs.

**Conclusions**

LncRNAs play vital roles in the pathogenesis of DCM. Manipulating specific IncRNAs with pharmacological
and genetic approaches to alter their expression impacts the development of DCM. In spite of limited data of specific lncRNAs in DCM, they are the potential targets/candidates for DCM. The future research needs to elucidate the regulation, function, and action mechanisms of more lncRNAs in the pathogenesis of DCM to search potential targets/candidates as diagnostic biomarkers of DCM and potential treatment of DCM.

Abbreviations

ANRIL: Antisense non-coding RNA in the INK4 locus; DCM: Diabetic cardiomyopathy; IGF2: Insulin-like growth factor-II; lncRNAs: Long noncoding RNAs; MALAT1: Metastasis-associated lung adenocarcinoma transcript; MIAT: Myocardial infarction-associated transcript; MT-LIPCAR: The mitochondrially encoded long non-coding cardiac associated RNA; SENCR: Smooth muscle and endothelial cell-enriched migration/differentiation-associated long noncoding RNA; STZ: Streptozotocin; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus

Acknowledgements

None.

Funding

This work was supported, in part, by a National Institutes of Health research grant P01GM 066730 (to Dr. Bosnjak) from the United States Public Health Services, Bethesda, Maryland, USA. The funding body had no role in the design of the study, collection, analysis, and interpretation of data, and in writing the manuscript.

Consent of publication

Not applicable.

Availability of data and materials

Not applicable.

Authors’ contributions

ZDG, ZJB, ML, and TP conceived the original idea. TP and JF collected and prepared the literature. ZDG, ZJB, ML, AD, and XB contributed to interpretation of the literature. ZDG and TP reviewed the literature and wrote the original manuscript. All authors read, discussed, and revised the final manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable-no human projects or tissue.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. 2Department of Ophthalmology, Stanford School of Medicine, 1651 Page Mill Road, Stanford, CA 94304, USA. 3Department of Pediatrics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. 4Department of Cell Biology, Neurology & Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. 5Department of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. 6Centre for Biotechnology, Anna University, Chennai, Tamil Nadu, India.
44. Anderson KM, Anderson DM, McAnally JR, Shelton JM, Bassel-Duby R, Olson EN. Transcription of the non-coding RNA upregulated conserved hand2 expression and heart development. Nature. 2016;539:433–6.

45. Liu CY, Zhang YH, Li RB, Zhou LY, An T, Zhang RC, Zhai M, Huang Y, Yan H. LncRNA CAF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardial transactivation. Nat Commun. 2018;9(29).

46. Xu Q, Du Y, Shu Y, Gao M, Sun F, Luo S, Yang T, Zhan L, Yuan Y, Chu W, Pan Z, Wang Z, Yang B, Lu Y. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci Rep. 2017;7:42657.

47. Wang K, Long B, Zhou LY, Liu F, Zhou QY, Liu CY, Fan Y, Li P. CARL IncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5:3596.

48. Zhang G, Sun H, Zhang Y, Zhao H, Fan W, Li J, Lu Y, Song Q, Zhang M. Shi H. Characterization of dysregulated IncRNA- mRNA network based on cRNA hypothesis to reveal the occurrence and recurrence of myocardial infarction. Cell Death Discov. 2018;4:35.

49. Zhang Z, Gao W, Long QQ, Zhang J, Li YF, Liu DC, Yan J, Yang Y, Wang LS. Increased plasma levels of IncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep. 2017;7:7491.

50. Piccoli MT, Gupta SK, Vire heck J, Foinquinos A, Samolovik S, Kramer FL, Garg A, Remke J, Kim Z, Bakari S, Thum T. Inhibition of the cardiac fibroblast- enriched IncRNA MEG3 prevents cardiac fibrosis and diastolic dysfunction. Circ Res. 2017;121:575–83.

51. Ounzain S, Burdet F, Roberson M, Pedrazzini T. Discovery and functional characterization of cardiac long non-coding RNAs. J Mol Cell Cardiol. 2015;89:17–26.

52. Devaux Y, Zangrando J, Schreoo B, Creemers EE, Pedrazzini T, Chang CP, Han P. Epigenetic and lncRNA regulation of cardiac function in development and ageing. Nat Rev Cardiovasc Dis. 2015;12:415–25.

53. Leti F, Di Stefano JK. Long non-coding RNAs as diagnostic and therapeutic targets in type 2 diabetes and related complications. Genes. 2017;8.

54. Leung A, Natarajan R. Long non-coding RNAs in diabetes and diabetic complications. Antioxid Redox Signal. 2017.

55. Lorenzen JM, Thum T. Long non-coding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol. 2016;12:360–73.

56. Virecke J, Thum T. Circulating long non-coding RNAs as biomarkers of cardiovascular disease and injury. Circ Res. 2017;120:381–99.

57. Zhou C, Jiang R, Lin X, Shao M. lncRNA H19 inhibits autophagy by epigenetically silencing of DIRAS3 in diabetic cardiomyopathy. Oncotarget. 2017;8:1429–37.

58. Li X, Wang H, Yao B, Xu W, Chen J, Zhou X. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Sci Rep. 2016;6:36340.

59. Gabory A, Jammes H, Dandolo L, The H19 locus. role of an imprinted non-coding RNA in growth and development. Bioessays. 2010;32:473–80.

60. Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. Nature. 1991;351:153–5.

61. DeChiara TM, Robertson EJ, Efratiadis A. Parental imprinting of the mouse raf and Rif genes. Proc Natl Acad Sci U S A. 1984;81:5523

62. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell. 1987;51:987–99.

63. Lustig O, Ariel I, Ilan J, Lev-Lehman E, De-Groot N, Hochberg A. Expression of the imprinted gene H19 in the human fetus. Mol Reprod Dev. 1991;25:1000.

64. Schwartz N, Matsuda M, Inoue A, Iwado T, Hori M, Hori T, et al. Essential role of TRF1 in the regulation of the imprinted H19 locus in the wild-type mouse. Mol Cell. 2001;64:37–47.

65. Chen LL. Linking long noncoding RNA localization and function. Trends Biochem Sci. 2016;41:761–72.

66. Sun X, Han Q, Luo H, Pan X, Ji Y, Yang Y, Chen H, Wang F, Lai W, Guan X, Zhang Q, Yang Y, Chu J, Yu J, Shao W, Deng Y, Li X. Profiling analysis of long non-coding RNAs in early postnatal mouse hearts. Sci Rep. 2017;7:43485.

67. Beermann J, Kirste D, Iwanov K, Lu D, Kleemiss F, Kumarswamy R, Schimmel K, Bar T, Thum T. A large shRNA library approach identifies IncRNA Ntep as an essential regulator of cell proliferation. Cell Death Differ. 2018;25:307–18.

68. Chang CP, Han P. Epigenetic and IncRNA regulation of cardiac pathophysiology. Biochim Biophys Acta. 2016;1863:1767–71.

69. Li Y, Du W, Zhao R, Hu L, Han R, Yue Q, Wu R, Li W, Zhao J. New insights into epigenetic modifications in heart failure. Front Biosci. 2017;22:239–47.

70. Wilk R, Hu J, Blotsky D, Krae HM. Diverse and pervasive subcellular distributions for both coding and long non-coding RNAs. Genes Dev. 2016;30:594–609.

71. Chen LL. Linking long noncoding RNA localization and function. Trends Biochem Sci. 2016;41:761–72.

72. Sun X, Han Q, Luo H, Pan X, Ji Y, Yang Y, Chen H, Wang F, Lai W, Guan X, Zhang Q, Yang Y, Chu J, Yu J, Shao W, Deng Y, Li X. Profiling analysis of long non-coding RNAs in early postnatal mouse hearts. Sci Rep. 2017;7:43485.

73. Quinn JJ, Ilik IA, Qu K, Georgiev P, Chu C, Akhtar A, Chang YH. Revealing long noncoding RNA architecture and functions using domain-specific chromatin isolation by RNA purification. Nat Biotechnol. 2014;32:933–40.

74. Dykes WS, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017;15:717–86.

75. Kretz M, Srapeshlitz Z, Chu C, Webster DE, Zehnder A, Qu K, Lee CS, Flockhart RJ, Groff AF, Chov J, Johnston D, Kim GE, Spaldke RC, Flynn RA, Zheng GX, Ayser S, Raj A, Rinn JL, Chang YH, Khayari PA. Control of somatic tissue differentiation by the long non-coding RNA TINCR Nature. 2013;493:231–5.

76. Markovich SJ, Edwards JR, Grossheider TC, de Guzman Strong C, Dom GW. Epigenetic coordination of embryonic heart expression by dynamically regulated long noncoding RNAs. Proc Natl Acad Sci U S A. 2014;111:12264–9.

77. Zhou X, Zhang W, Jin M, Chen J, Xu W, Kong X. LncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis. 2017;8:e2929.

78. Lu L, Li T, Li X, Xu C, Li Q, Jiang H, Li Y, Yu Y, Yan H, Huang Q, Zhou Y, Zhang M, Shan H, Jiang H. The IncRNA Plscr4 regulates hypertrophy by regulating miR-214. Mol Ther Nucleic Acids. 2018;10:387–97.

79. Liu Y, Zhou D, Li G, Ming X, Tu Y, Tian J, Liu H, Yu B. Long non coding RNA-UCAC1 contributes to cardiomyocyte apoptosis by suppression of p27 expression. Cell Physiol Biochem. 2015;35:1986–98.

80. Rayner KJ, Liu PP. Long noncoding RNAs in the heart: the regulatory roadmap of cardiovascular development and disease. Circ Cardiovasc Genet. 2016;9:101–3.

81. Schmitz SU, Grote P, Herrmann RG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2017;74:2991–509.

82. Xue Z, Hennelly S, Doyle B, Gulati AA, Nowikova N, Sanbonmatsu KY, Boyar LA. A Grinch motif in the IncRNA Brachetheart interacts with a zinc-finger transcription factor to specify the cardiovascular lineage. Mol Cell. 2016;64:37–50.

83. Warms JD, Anderson KM, Alexander JM, Truty RM, Shrikumar A, Li F, Etienne KE, Ding H, Wylie JN, Pico AR, Capra JA, Enwin G, Katmann SJ, Keller GM, Srivastava D, Levine SS, Pollard KS, Funke A, Boyer LA, Bruneau BG. Dynamic and coordinated epigenetic regulation of developmental transitions in the cardiac lineage. Cell. 2012;151:206–20.

84. Anderson KM, Anderson DM, McArally JR, Shelton J, Bassel-Duby R, Olson EN. Transcription of the non-coding RNA upregulated conserved hand2 expression and heart development. Nature. 2016;539:433–6.

85. Liu CY, Zhang YH, Li RB, Zhou LY, An T, Zhang RC, Zhai M, Huang Y, Yan KW, Dong YH, Ponnusamy M, Chan S, Xu S, Wang Q, Zhang J, Wang K. LncRNA CAF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardial transactivation. Nat Commun. 2018;9:29.
Canzian F. Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Sci Rep. 2016;6:39565.

107. Rahimi E, Ahmadi A, Boroumand MA, Mohammad Soltani B, Behmanesh M. Association of ANRIL expression with coronary artery disease in type 2 diabetic patients. Cell J. 2018;20:41–5.

108. Pant T, Dhanasekaran A, Bosnjak ZJ, Ge ZD. Microarray analysis of long noncoding RNAs in the heart and plasma of type 2 diabetic db/db mice. FASEB J. 2018;32:AS80517.

109. Zur Brugege J, Einspanier R, Sharbatli S. A long journey ahead: long non-coding RNAs in bacterial infections. Front Cell Infect Microbiol. 2017;7:955.

110. Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127:761–71.

111. Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016;44:863–77.

112. Prabhakar B, Zhong XB, Rasmussen TP. Exploiting long noncoding RNAs as pharmacological targets to modulate epigenetic diseases. Yale J Biol Med. 2017;90:73–86.

113. Zhou T, Kim Y, MacLeod AR. Targeting long noncoding RNA with antisense oligonucleotide technology as cancer therapeutics. Methods Mol Biol. 2016;1402:199–213.

114. Amadio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zucala V, Rossi M, Neri A, Munshi NC, Tagliatere P, Tassone P. Drugging the IncRNA MALAT1 via LNA-gampeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018.

115. Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexian M, Maric D, Maison D, Nemir M, Young RA, Schroen B, Gonzalez A, Ounzain S, Pedrazzini T. The long noncoding RNA WISPER controls cardiac fibrosis and remodeling. Sci Transl Med. 2017;9.

116. Li DY, Busch A, Jin H, Chemoguboeva E, Pelisek J, Karlson J, Sennblad B, Liu S, Lao S, Hofmann P, Backlund A, Blen SM, Roy J, Eriksson P, Dacken B, Ramanujam D, Duek A, Engelhardt S, Boon RA, Eckstein HH, Spin JM, Tiao PS, Maegdefessel L. H19 induces abdominal aortic aneurysm development and progression. Circulation. 2018. https://doi.org/10.1161/CIRCULATIONAHA.117.032184.

117. d’Ydewalle C, Ramos DM, Pyles NJ, Ng SY, Gour M, Plaoto CM, Ling K, Kong L, Ward AJ, Rubin LL, Rigo F, Bennett CF, Surner C. The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron. 2017;93:66–79.

118. Zhu S, Li W, Liu J, Chen CH, Liao Q, Xu P, Xu H, Xiao T, Cao Z, Peng J, Yuan P, Brown M, Liu XS, Wei W. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-CAS9 library. Nat Biotechnol. 2016;34:1279–86.

119. Aparicio-Prat E, Aman C, Sala I, Bosch N, Guigo R, Johnson R, DECKO. Single-o, dual-crispr deletion of genomic elements including long non-coding RNAs. BMC Genomics. 2015;16:846.